This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Jimmy Weterings, PhD
Vice President Research, RNA Therapeutics & Delivery at Sirnaomics


Jimmy Weterings, PhD is Senior Director, Head of Technology Development at Sirnaomics, USA.

Jimmy has had a tight bond with Oligonucleotides since 2002, performing research on PNA (conjugates) in the van Boom group at Leiden University, the Netherlands and targeted SSO conjugates at Prosensa. During his Ph.D at Leiden University he synthesized and studied CpG Oligonucleotide and other TLR ligand containing conjugates. At Cenix BioScience, he developed targeted siRNA conjugates for CNS delivery. And at Cristal Therapeutics he led various projects on the (targeted) nanomedicine delivery of oligonucleotide in oncology. In 2019 he joined AstraZeneca in Sweden, to further the advancement of (targeted) oligonucleotide therapeutics. Since December 2022, Jimmy joined Sirnaomics in the USA as Senior Director, designing novel oligonucleotide chemistries and targeted version thereof.

Jimmy (co-)authored 13 articles and holds several patents for drug delivery enabling technologies, including the most recent one on TMTHSI, ClicR® exclusively licensed to Synaffix and commercially available for R&D purposes.

Agenda Sessions

  • GalAhead™: A Proprietary GalNAc-RNAi Therapeutic Platform to Downregulate Single and Multiple Genes